Paul A. Friedman - Jan 16, 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Chief Executive Officer, Director
Signature
/s/ Brian J. Lynch**
Stock symbol
MDGL
Transactions as of
Jan 16, 2023
Transactions value $
$0
Form type
4
Date filed
1/18/2023, 07:00 PM
Previous filing
Jun 22, 2022
Next filing
Jun 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Award $0 +26.7K $0.00 26.7K Jan 16, 2023 Direct F1
holding MDGL Common Stock 161K Jan 16, 2023 Direct
holding MDGL Common Stock 656K Jan 16, 2023 By SQN LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.
F2 The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

**As attorney-in-fact for Reporting Person